Rhumbline Advisers Rain Therapeutics Inc. Transaction History

Rhumbline Advisers

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$0.84 - $1.22 $1,940 - $2,818	-2,310 Reduced 12.61%	16,007 $19,000
Q3 2023 Nov 09, 2023	BUY	$0.82 - $1.42 $2,342 - $4,056	2,857 Added 18.48%	18,317 $15,000
Q2 2023 Aug 08, 2023	BUY	$1.09 - $9.93 $16,851 - $153,517	15,460 New	15,460 $18,000
Q2 2022 Aug 11, 2022	SELL	$2.21 - $5.56 $25,014 - $62,933	-11,319 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$5.07 - $13.68 $3,675 - $9,918	725 Added 6.84%	11,319 $57,000
Q4 2021 Feb 10, 2022	BUY	$11.91 - $17.0 $126,174 - $180,098	10,594 New	10,594 $136,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.